Who
Gregg H. Alton
Director
Company insider
Files Form 4 as: Director, Novavax; Director, Corcept Therapeutics; Director, Lunai Bioworks; Chief Patient Officer, Gilead Sciences; Director, Celladon; Director, Sonoma Pharmaceuticals.
In numbers
- Trades disclosed
- 1,026
- Buys
- 0
- Sells
- 166
- Bought
- $0
- Sold
- $183.9M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 25 Jan 2006
- Last trade
- 20 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Jun 2026filed 23 Jun 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —18,880 | filing |
| 20 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,880 at $0.00 | filing |
| 20 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,880 at $0.00 | filing |
| 20 Jun 2026filed 23 Jun 2026 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —18,880 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,270 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,180 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,270 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,180 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | CORT Corcept Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | CORT Corcept Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | $182K28,326 at $6.42 | filing |
| 20 Jun 2025filed 24 Jun 2025 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,884 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,420 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | NVAX NovavaxBiotechnology | SEC FORM 4 Code M | —10,420 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | CORT Corcept Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 31 Dec 2024filed 5 Feb 2025 | NVAX NovavaxBiotechnology | SEC FORM 4 Code A | $17K1,982 at $8.61 | filing |
| 30 Sep 2024filed 5 Feb 2025 | NVAX NovavaxBiotechnology | SEC FORM 4 Code A | $17K1,311 at $12.77 | filing |
| 30 Jun 2024filed 5 Feb 2025 | NVAX NovavaxBiotechnology | SEC FORM 4 Code A | $17K1,202 at $13.93 | filing |
| 25 Jun 2024filed 27 Jun 2024 | LNAI Lunai Bioworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,137 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | NVAX Novavaxoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,670 at $0.00 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?GILD · fool.com · 18 Oct 2026Gilead Sciences Clears Its February High at $153.54GILD · 247wallst.com · 15 Oct 2026Gilead Sciences, Inc. $GILD Stock Acquired by First Citizens Bank & Trust Co.GILD · dailypolitical.com · 14 Oct 2026
0 headlines in the last 90 days name Gregg H. Alton; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.